The Translational Genomics Research Institute (TGen) has uncovered possible genetic origins of breast cancer that spreads to the brain, according to a first-of-its-kind study published in the scientific journal PLOS ONE.
The compendium of genetic targets uncovered by TGen now can be used to identify potential new methods of diagnosis and new drug therapies for the estimated 45,000 patients in the U.S. each year whose cancer spreads from the breast to the brain.
The 3-year study is significant since these patients currently have few treatments options—surgery and radiation—and they usually are ineligible for clinical drug trials. Their prognosis is poor, with fewer than 2 percent surviving more than two years
"This is really a significant problem and a huge unmet need. We now want to dig deeper and uncover more specific genomic links and study new ways to treat these patients so we can improve outcomes," said Dr. Bodour Salhia, an Assistant Professor in TGen's Integrated Cancer Genomics Division and the study's lead and co-senior author.
"In this study, we see that breast-brain metastasis retain many features found in primary breast cancer, but we still need to better understand the differences," said Dr. Salhia. "Knowing the key drivers of brain metastasis may lead to preventive measures, as well."
After lung cancer, breast cancer is the second most common cancer that spreads to the brain. Chemotherapy generally has not been used to treat brain cancer, because of the blood-brain barrier that exists between the bloodstream and the cerebrospinal fluid surrounding the brain. However, some small molecule drugs can cross this barrier and form the basis of targeted therapies.
The overall goal of the TGen study was to look at genomic and epigenomic events to understand the causes of breast cancer brain metastatic lesions, and identify potential new therapeutic targets.
The TGen team performed deep genomic profiling, integrating gene copy number, gene expression and DNA methylation datasets on a collection of 35 breast-brain metastases samples. The study, Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis, published Jan. 29, is the first of its kind to incorporate all of those avenues of inquiry in the study of this disease.
Some of the common genetic alterations identified in the study were gains and losses in chromosome 8, as well as cell proliferation and cell-cycle progression—key mechanisms of cancer caused by genetic alterations—linked to the genes AURKA, AURKB and FOXM1.
"This groundbreaking study sets the stage for more exacting research, using the latest genomic technologies and aimed at developing new therapies that could help the tens of thousand of patients who urgently need our help," said Dr. Nhan Tran, an Associate Professor of TGen's Cancer and Cell Biology Division and the study's other co-senior author.
Explore further: Scientists link protein with breast cancer's spread to the brain
Medical Xpress on facebook
Related Stories
Scientists link protein with breast cancer's spread to the brain
Jan 06, 2014
A cancer-research team at the University of Wisconsin-Madison has identified a protein that may be a major culprit when breast cancer metastasizes to the brain.
Breast cancer cells disguise themselves as neurons to cause brain tumors
Jan 15, 2014
Treatment and "cure" of breast cancer doesn't ensure that the disease won't spread to the brain. Too often, sometimes years after an initial diagnosis and remission, breast cancer cells are discovered growing as new tumors ...
First large-scale study of whole-genome testing helps identify best treatment for women with advanced breast cancer
Feb 06, 2014
The first large-scale study testing all the DNA—the entire genome—of tumor cells from more than 400 women with advanced breast cancer has identified individuals with a good chance of benefiting from specific treatments ...
Breast cancer prognosis associated with oncometabolite accumulation
Dec 09, 2013
The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the Journal of Clinical Investigation Stefan Ambs and colleagues at the Nation ...
Study shows TWEAK-Fn14 is drug target for cancer
Nov 08, 2013
(Medical Xpress)—A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, ...
Recommended for you
ASTRO and SSO issue consensus guideline on margins for breast-conserving surgery with WBI
46 minutes ago
The American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO) are pleased to announce the publication of the consensus guideline on margins for breast-conserving surgery with whole-breast ...
President's panel calls for more girls, boys to get HPV vaccine
1 hour ago
(HealthDay)—Too few American girls and boys are getting vaccinated against the cancer-causing human papillomavirus (HPV), the President's Cancer Panel reported Monday.
Study identifies a key cellular pathway in prostate cancer
1 hour ago
Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor—the cellular component ...
Weakness exposed in most common cancer gene
4 hours ago
NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies ...
Normal enzyme aids a mutant one to fuel blood cancer's growth
4 hours ago
Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs ...
EORTC characterizes responders and survivors on pazopanib for advanced soft tissue sarcoma
6 hours ago
An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for me ...
User comments
© Medical Xpress 2011-2014, Science X network
The Translational Genomics Research Institute (TGen) has uncovered possible genetic origins of breast cancer that spreads to the brain, according to a first-of-its-kind study published in the scientific journal PLOS ONE.
The compendium of genetic targets uncovered by TGen now can be used to identify potential new methods of diagnosis and new drug therapies for the estimated 45,000 patients in the U.S. each year whose cancer spreads from the breast to the brain.
The 3-year study is significant since these patients currently have few treatments options—surgery and radiation—and they usually are ineligible for clinical drug trials. Their prognosis is poor, with fewer than 2 percent surviving more than two years
"This is really a significant problem and a huge unmet need. We now want to dig deeper and uncover more specific genomic links and study new ways to treat these patients so we can improve outcomes," said Dr. Bodour Salhia, an Assistant Professor in TGen's Integrated Cancer Genomics Division and the study's lead and co-senior author.
"In this study, we see that breast-brain metastasis retain many features found in primary breast cancer, but we still need to better understand the differences," said Dr. Salhia. "Knowing the key drivers of brain metastasis may lead to preventive measures, as well."
After lung cancer, breast cancer is the second most common cancer that spreads to the brain. Chemotherapy generally has not been used to treat brain cancer, because of the blood-brain barrier that exists between the bloodstream and the cerebrospinal fluid surrounding the brain. However, some small molecule drugs can cross this barrier and form the basis of targeted therapies.
The overall goal of the TGen study was to look at genomic and epigenomic events to understand the causes of breast cancer brain metastatic lesions, and identify potential new therapeutic targets.
The TGen team performed deep genomic profiling, integrating gene copy number, gene expression and DNA methylation datasets on a collection of 35 breast-brain metastases samples. The study, Integrated Genomic and Epigenomic Analysis of Breast Cancer Brain Metastasis, published Jan. 29, is the first of its kind to incorporate all of those avenues of inquiry in the study of this disease.
Some of the common genetic alterations identified in the study were gains and losses in chromosome 8, as well as cell proliferation and cell-cycle progression—key mechanisms of cancer caused by genetic alterations—linked to the genes AURKA, AURKB and FOXM1.
"This groundbreaking study sets the stage for more exacting research, using the latest genomic technologies and aimed at developing new therapies that could help the tens of thousand of patients who urgently need our help," said Dr. Nhan Tran, an Associate Professor of TGen's Cancer and Cell Biology Division and the study's other co-senior author.
Explore further: Scientists link protein with breast cancer's spread to the brain
Medical Xpress on facebook
Related Stories
Scientists link protein with breast cancer's spread to the brain
Jan 06, 2014
A cancer-research team at the University of Wisconsin-Madison has identified a protein that may be a major culprit when breast cancer metastasizes to the brain.
Breast cancer cells disguise themselves as neurons to cause brain tumors
Jan 15, 2014
Treatment and "cure" of breast cancer doesn't ensure that the disease won't spread to the brain. Too often, sometimes years after an initial diagnosis and remission, breast cancer cells are discovered growing as new tumors ...
First large-scale study of whole-genome testing helps identify best treatment for women with advanced breast cancer
Feb 06, 2014
The first large-scale study testing all the DNA—the entire genome—of tumor cells from more than 400 women with advanced breast cancer has identified individuals with a good chance of benefiting from specific treatments ...
Breast cancer prognosis associated with oncometabolite accumulation
Dec 09, 2013
The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the Journal of Clinical Investigation Stefan Ambs and colleagues at the Nation ...
Study shows TWEAK-Fn14 is drug target for cancer
Nov 08, 2013
(Medical Xpress)—A cellular pathway interaction known as TWEAK-Fn14, often associated with repair of acute injuries, also is a viable target for drug therapy that could prevent the spread of cancer, especially brain cancer, ...
Recommended for you
ASTRO and SSO issue consensus guideline on margins for breast-conserving surgery with WBI
46 minutes ago
The American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO) are pleased to announce the publication of the consensus guideline on margins for breast-conserving surgery with whole-breast ...
President's panel calls for more girls, boys to get HPV vaccine
1 hour ago
(HealthDay)—Too few American girls and boys are getting vaccinated against the cancer-causing human papillomavirus (HPV), the President's Cancer Panel reported Monday.
Study identifies a key cellular pathway in prostate cancer
1 hour ago
Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor—the cellular component ...
Weakness exposed in most common cancer gene
4 hours ago
NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies ...
Normal enzyme aids a mutant one to fuel blood cancer's growth
4 hours ago
Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs ...
EORTC characterizes responders and survivors on pazopanib for advanced soft tissue sarcoma
6 hours ago
An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for me ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment